September 28, 2026 · AxonCPT Team · ADHD assessment, clinical practice, CPT

Detecting Feigned ADHD: Symptom and Performance Validity

Malingering in an ADHD assessment means a patient is intentionally exaggerating or fabricating symptoms, usually to obtain a stimulant prescription, academic or workplace accommodations, or medication to sell or misuse. It’s a real concern in adult evaluations specifically, and no single tool — not a rating scale, not an interview, not a continuous performance test (CPT) — reliably catches it alone. This guide walks through what symptom and performance validity assessment actually measure, what the recent evidence shows about using CPTs for this purpose, and where the honest limits are.

Psychologist taking notes while listening to a patient during an ADHD assessment interview Photo by Vitaly Gariev on Unsplash

Why this matters clinically, not just diagnostically

Stimulant misuse and diversion carry real safety risk, including overdose and dangerous drug interactions, and clinicians who prescribe based on an unverified self-report are exposed both clinically and legally [1]. A 2025 commentary in the Croatian Medical Journal cites a nationally representative survey finding that roughly 20% of past-year nonmedical prescription stimulant users reported exaggerating symptoms specifically to obtain a prescription [2]. Documented motivations for feigning ADHD symptoms include seeking cognitive performance enhancement, pursuing academic or workplace accommodations, and diversion for recreational use or resale [1][2]. None of this means most patients presenting with ADHD symptoms are being untruthful — base rates of genuine ADHD are substantial, and most patients reporting symptoms are doing so accurately. It means a structured approach to validity, applied consistently, protects both patients who are telling the truth and the integrity of the evaluation.

Symptom validity and performance validity are not the same thing

These two terms get used loosely, but they measure different things. Symptom validity refers to how accurately a patient’s self-reported or observer-reported symptoms reflect their actual experience — this is what a rating scale infrequency index or a symptom validity scale targets. Performance validity refers to whether a patient’s actual task performance reflects their true ability, independent of what they say about themselves — this is what an embedded validity indicator within a cognitive test, including a CPT, targets [3].

A 2025 study using network and factor analysis on a clinical sample of 461 adults referred for ADHD evaluation found that performance validity tests did not form a cohesive network with CPT measures, and that symptom reports — including embedded symptom validity scales — clustered separately from performance-based attention measures [3]. The authors’ conclusion is direct: these are largely independent sources of information, and clinicians should assess them separately rather than assuming one predicts the other [3]. In practice, that means a patient can produce credible-looking self-report and less credible task performance, or the reverse, and a full evaluation should check both.

Can a CPT detect invalid effort? What the 2025 meta-analysis found

The most current synthesis on this question is a 2025 systematic review and meta-analysis in the journal Assessment, which pooled 18 studies (n = 3,021 participants, 67 effect sizes — eight simulation studies where participants were asked to fake ADHD, and ten criterion-group studies comparing clinically identified credible and noncredible responders). The pooled effect size for CPTs distinguishing credible from noncredible performance was g = 0.73, a moderate-to-large effect, with study design (simulation versus criterion-group) and sample type (student versus non-student) both moderating the result [4].

That’s a meaningfully positive finding at the group level — CPT performance does differ, on average, between credible and noncredible responders. It is not the same as saying a CPT can reliably flag an individual patient as malingering. Group-level effect sizes describe average separation between two populations; they don’t translate directly into a diagnostic accuracy figure for a single administration, and the review itself notes substantial variability by study design [4].

Embedded validity indicators: promising, but limited at the individual level

Some CPTs, most studied here being the Conners CPT-3, have been examined for specific embedded scores that flag possible invalid performance. A 2021 study of 197 military veterans evaluated for ADHD at a VA hospital found that five CPT-3 variables — detectability (d′), omission errors, commission errors, hit reaction time standard deviation, and a reaction-time interstimulus-interval change score — significantly predicted validity status on an independent memory-based validity test (the TOMM) [5]. The authors concluded these scores “may be used as indicators of invalid performance but should not be used to rule out invalid performance,” and that they’re best treated as one component in a multi-point validity approach, not a standalone screen [5].

A larger 2023 study of 201 adults referred for ADHD and/or specific learning disorder evaluation, comparing 159 classified as credible against 42 classified as noncredible using five criterion measures, found that while several individual and composite CPT-3 validity indicators reached minimally acceptable classification accuracy (AUC 0.43–0.78) in ROC analysis, their sensitivity was low — 0.16 to 0.45 for individual indicators, and 0.23 to 0.35 for composite indicators — once the threshold was set to maintain specificity at or above 90% [6]. In plain terms: at cutoffs strict enough to avoid falsely flagging credible patients, these embedded indicators caught well under half of the noncredible group. That’s a meaningful, honest limitation, and it’s consistent with the broader CPT accuracy literature discussed in CPT accuracy for ADHD: what the meta-analyses show.

AxonCPT does not publish or claim a validated embedded performance-validity algorithm. The research above describes specific scoring approaches studied within specific products (largely the Conners CPT-3), not a general property of every CPT on the market. Treat any performance-validity claim, from any vendor, as something to verify against a peer-reviewed study of that specific product before relying on it.

Rating scales alone are easier to influence

Self-report and observer-report rating scales are useful and validated tools, but they’re also the easiest instrument in an ADHD evaluation to consciously shape, because the respondent knows exactly what a “high” ADHD score looks like. Researchers have built subtle scales specifically to address this: the Subtle ADHD Malingering Screener (SAMS), a 10-item self-report measure whose true purpose is disguised from the respondent, reported 90.3% sensitivity and 80.1% specificity for distinguishing instructed malingerers from genuine ADHD and control groups in its development study [7]. That’s a notably stronger classification result than the CPT-based embedded indicators above, though it comes from a single development study using instructed (simulated) malingerers rather than real-world clinical cases, which tends to produce cleaner separation than criterion-group studies of actual patients. It illustrates why rating scales and performance-based measures are worth combining rather than treating either as sufficient alone — see ADHD rating scales vs. objective testing for the broader case for using both.

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

A practical, multi-method approach

No single tool covered here is a reliable standalone lie detector, and treating it as one risks both false reassurance and wrongly denying care to a patient who is being truthful. A more defensible approach combines several sources of evidence:

  1. Collateral history, where available — a parent, partner, or old school or employment records describing childhood-onset symptoms are harder to fabricate consistently than a single self-report.
  2. Longitudinal consistency. Symptoms and impairment that have been documented over years, across settings, are more convincing than a first presentation built around a specific, narrow request.
  3. Standardized rating scales with attention to internal consistency, including infrequency or validity indices where the instrument includes one.
  4. An objective performance measure, interpreted as one data point, not a verdict. See what a continuous performance test measures for how a CPT fits into that broader picture.
  5. A clear, documented reasoning trail. When multiple sources converge, say so in the chart. When they diverge, document that too, and explain how you weighed it — that record protects the patient and the clinician regardless of which way the case resolves.
  6. Referral to formal neuropsychological evaluation for high-stakes or ambiguous cases, where dedicated, validated performance and symptom validity tests can be administered as part of a comprehensive battery — something a brief CPT in a prescribing visit isn’t designed to replace.

How this looks in practice

A PMHNP evaluating an adult who requests a stimulant after limited prior history might work through this sequence:

  1. Take a full developmental and functional history, seeking childhood-onset symptoms and collateral confirmation where possible.
  2. Administer standardized rating scales, reviewing for internally inconsistent or extreme response patterns.
  3. Add an objective attention measure. With objective ADHD testing with AxonCPT, the patient completes a standardized ~16-minute test from home, and the report compares performance against age- and sex-matched norms — one additional, independent data point alongside the interview and scales, not a validity verdict.
  4. Weigh convergence and divergence explicitly, and document the reasoning either way before prescribing a controlled substance.
  5. Escalate to formal psychological or neuropsychological testing when the picture stays unclear or the stakes (for example, a request centered heavily on stimulant access with little collateral support) warrant it.

You can see what an AxonCPT report looks like to understand what kind of data point it adds to that process.

Frequently asked questions

Can a CPT prove a patient is malingering? No single CPT administration should be treated as proof. Group-level research shows CPT performance differs, on average, between credible and noncredible responders (g = 0.73 in a 2025 meta-analysis), but individual embedded validity indicators studied in specific products show low sensitivity once specificity is set high enough to avoid false flags [4][6].

Are symptom validity and performance validity the same thing? No. Symptom validity concerns whether self- or observer-reported symptoms are accurate; performance validity concerns whether task performance reflects true ability. A 2025 study found these don’t form a single unified construct and should be assessed independently [3].

Is malingered ADHD common? Estimates vary by population and method. A cited nationally representative survey found about 20% of past-year nonmedical prescription stimulant users reported exaggerating symptoms to obtain a prescription [2]. That figure describes a specific population (people already using stimulants nonmedically), not the general rate of feigning among all patients presenting for ADHD evaluation.

What should I do if I suspect a patient is exaggerating symptoms? Don’t rely on a single tool or a single interaction. Combine history, collateral information where available, rating scales, and objective performance data, document your reasoning, and consider a referral for formal neuropsychological evaluation with dedicated validity testing in ambiguous or high-stakes cases.

Does AxonCPT detect malingering? No. AxonCPT reports standardized attention and performance metrics against normative data; it does not publish or claim a validated malingering or performance-validity algorithm. Any validity-detection claim for any CPT product should be checked against peer-reviewed research on that specific product before you rely on it.

Start testing your patients with AxonCPT

A defensible evaluation combines history, rating scales, and objective data — no single piece carries the whole decision. AxonCPT adds a standardized, norm-referenced attention measure to that picture, with 2 free tests every month and no card required. Create your free AxonCPT account or learn more at axoncpt.com.

References

  1. Sadek J. Malingering and Stimulant Medications Abuse, Misuse and Diversion. Brain Sci. 2022;12(8):1004.
  2. Todorić Laidlaw I, Caratan S, Štracak M. The misuse of prescription stimulants: between overdiagnosing and malingering. Croat Med J. 2025;66(5):307-308.
  3. Raasch E, Fuermaier ABM, Kneidinger J, Albrecht B, Christiansen H. Joint Factor Performance Validity?—Network and Factor Structure of Performance Validity Measures in the Clinical Evaluation of Adult ADHD. Behav Sci. 2025;15(8):1108.
  4. Toptas P, Dekkers TJ, Groenman AP, Gaastra GF, de Waard D, Fuermaier ABM. Evaluating Continuous Performance Tests as Embedded Measures of Performance Validity in ADHD Assessments: A Systematic Review and Meta-Analysis. Assessment. Published online December 28, 2025.
  5. Ord AS, Miskey HM, Lad S, Richter B, Nagy K, Shura RD. Examining embedded validity indicators in Conners continuous performance test-3 (CPT-3). Clin Neuropsychol. 2021;35(8):1426-1441.
  6. Robinson A, Reed C, Davis K, Divers R, Miller L, Erdodi LA, Calamia M. Settling the Score: Can CPT-3 Embedded Validity Indicators Distinguish Between Credible and Non-Credible Responders Referred for ADHD and/or SLD? J Atten Disord. 2023;27(1):80-88.
  7. Ramachandran S, Holmes ER, Rosenthal M, Banahan BF, Young J, Bentley JP. Development of the Subtle ADHD Malingering Screener. Assessment. 2019;26(5).